The effect on survival of including HLA-DPB1 in a 12-allele matching strategy was retrospectively evaluated in 130 patients with acute leukaemia and myelodysplasia undergoing T-cell-depleted PBSC transplantation using unrelated donors. Patients received alemtuzumab in vivo T-cell depletion as part of a myeloablative (MA; n ¼ 61) or reduced-intensity conditioning regimen (n ¼ 69). No difference in OS was seen with single-locus mismatching (mm) when 10 conventional alleles (HLA-A, B, C, DRB1 and DQB1) were considered. However, the addition of HLA-DPB1 matching data proved highly discriminatory. Mismatches were identified in 87% of patients previously considered fully matched (1DPmm ¼ 49pts: 2DPmm ¼ 28pts), and in the 9/10 group 22 patients were reclassified as double and 16 as triple mismatches. In 10/10 transplants, there was a distinct trend to poorer OS with double DPB1 mm. If all 12 loci were considered, 98% of single mm were at HLA-DPB1. Furthermore, cumulative mm at two or more loci was associated with significantly poorer 3-year OS (34% vs 48%, P ¼ 0.013: hazard ratio 1.8 (95% confidence interval 1.14-3.06; P ¼ 0.017), although his detrimental effect was only apparent using MA conditioning, in which reduced OS was associated with increased chronic GVHD (61% vs 16%, P ¼ 0.018) and nonrelapse mortality (30% vs 9%, P ¼ 0.039).
INTRODUCTION
High-resolution matching of HLA-A, B, C, DRB1 and DQB1 alleles has improved outcomes for many leukaemic patients receiving unrelated donor haemopoietic stem cell transplants. 1, 2 Center for International Blood and Marrow Transplant Research data, predominantly in T-replete transplants, shows a detrimental effect of mismatching (mm) on OS that is dependent on disease stage. 1 In contrast, T-depleted transplants may be intrinsically more permissive of mismatches at all stages, especially when reduced-intensity conditioning (RIC) is employed. 3, 4 HLA-DP is a third HLA class II Ag. The gene encoding the b-polypeptide chain (HLA-DPB1) is highly polymorphic and responsible for most of the phenotypic heterogeneity of the HLA-DP molecule. 5 Unless specifically selected, the majority of transplants will be mismatched for at least one DPB1 allele owing to weak linkage disequilibrium, dependent on a recombination hot spot between the HLA-DQ and DP loci. 6 As a result, HLA-DPB1 disparity is reported to be present in up to 5-10% of siblings and in 60-90% of unrelated donor transplants. [7] [8] [9] HLA-DPB1 matching is not included in most donor selection algorithms, despite a growing body of evidence reporting a significant impact of disparity at this locus on post transplant complications. 4, [10] [11] [12] [13] [14] [15] [16] HLA-DP molecules present antigenic peptides to T cells, and in the transplant setting allogeneic HLA-DP-specific T cells have been identified in GVHD and GVL reactions. [17] [18] [19] In T-replete transplants, the effect of mm HLA-DPB1 has been an increase in both GVHD and GVL resulting in a reduced relapse rate (RR), but at the expense of increased nonrelapse mortality (NRM). In T-depleted transplants, alemtuzumab seems to allow single DPB1 mm, but multiple HLA mm, including HLA-DPB1, may adversely affect outcomes. 4 A further subtlety of HLA-DPB1 matching is the ability to predict functional immunogenic potential between pairs of mismatched DP loci. 20 This functional T-cell epitope modelling has allowed the identification of permissive or nonpermissive DPB1 mm. 21 Recently, a large registry study in T-replete BM recipients receiving myeloablative (MA) conditioning has demonstrated significantly worse outcomes for nonpermissive mm in both 9/ 10 and 10/10 matched recipients owing to increased NRM. However, this impact of T-cell epitope on outcomes has not been universally reported. 22 To date, the bulk of published data describe outcomes in T-cellreplete transplants, many performed more than 10 years ago, the majority using MA conditioning and BM as the stem cell source. Here, we present data from a standardized cohort of PBSC transplantation patients, all receiving in vivo T-cell depletion with alemtuzumab. We examined the effect of HLA-DPB1 mm, alone and in combination with HLA-A, B, C, DRB1 and DQB1 mm, on transplant outcomes.
PATIENTS AND METHODS Patients
This was a retrospective study performed on patients who were transplanted for acute leukaemia or myelodysplasia between January 1 2005 and July 2012. High-resolution HLA-A, B, C, DRB1, DQB1 and DPB1 typing was available for all donor-recipient pairs. For those who had undergone transplantation between 2005 and 2010, ethical approval was obtained to retrospectively perform high-resolution HLA typing on stored DNA. From 2010 onwards, these data were collected prospectively.
HLA typing HLA-A, B and C high-resolution typing was performed on selected pairs (transplanted between 2005 and 2010) by PCR-SSP subtyping (Olerup SSP AB, Stockholm, Sweden). From 2010, all patients and donors were typed to high resolution by sequence-based typing (GenDx, Utrecht, The Netherlands). In addition, patients and donors with gaps in their highresolution HLA-A, B and C typing by PCR-SSP were retrospectively tested by sequence-based typing. All patients and donors were HLA-DRB1-and DQB1-typed to high resolution (second field) using PCR-SSP subtyping kits (Olerup SSP AB). All patients and donors were HLA-DPB1-typed by Luminex PCR-SSO typing (Lifecodes, Immucor, Norcross, GA, USA). Any ambiguities and expression mutations were resolved using PCR-SSP subtyping (Olerup SSP AB).
Conditioning regimen
All patients received alemtuzumab in the conditioning regimen. Patients undergoing RIC transplants received a total dose of 100 mg over 5 days, whereas MA recipients received a total dose of 50 mg over 5 days. 1, 23 ) , with the exception of two patients transplanted under cytogenetic or molecular persistence. Specifically, AML patients were transplanted in CR2 or high-risk CR1. High-risk features were adverse cytogenetics, secondary AML and requirement of more than one cycle of chemotherapy to obtain remission. Later, the MRC AML17 risk score was used to assign risk status (http:// aml17.cardiff.ac.uk). Patients transplanted for ALL (n ¼ 29) were transplanted in CR1 (n ¼ 14) if they had high-risk diseases such as high white cell count at diagnosis, were older or had adverse cytogenetics, including Ph-positive disease (n ¼ 7). No early-stage leukaemia or MDS patients were transplanted, and patients with CML were excluded. Myelodysplasia patients (n ¼ 23) were either International Prognostic Scoring System (IPSS) Int-2 or high risk. This group (with two AML patients 4CR2) comprised our high-risk group (n ¼ 25). Median follow-up for survivors was 24 months.
Details of matching data are shown in Table 2 . Eighty-nine transplants (70%) were from a 10/10 matched donor and 39 (30%) from a 9/10 matched donor. Two patients with single DRB1, DQB1 and DPB1 mismatches were excluded from the 10-allele analysis but were retained for analysis of 12 alleles. When matching at 12 loci was considered, 52% of cases had two or more mm, and 48% were either 11 or 12/12 matched. All but one of the 11/12 group were single DPB1 mm.
Mismatching at a single locus for HLA-A, B, C, DR and DQ has no effect on OS In all patients combined, the 1-year OS was 61%, 2-year OS was 41% and 5-year OS was 36%. There was no difference in outcome whether the patients received an MA or RIC regimen. There was no effect on OS of mm at a single HLA locus when HLA-A, B, C, DRB1 and DQB1 loci were considered. Overall, the estimated 5-year OS was 43% in 10/10 transplants and 33% in 9/10 transplants. There were no differences in outcomes in 9/10 vs 10/10 patients transplanted using either MA (P ¼ 0.25) or RIC (P ¼ 0.26) regimens (Figures 1a-c) .
Impact of DPB1 mismatches alone in 10/10 matched pairs For patients who received 10/10 matched transplants, there was a sequential improvement in OS as the degree of matching for HLA-DPB1 increased. Although this was not statistically significant ( Figure 1d ), there was a distinct trend to worse OS rates for double DPB1 mm. This was most marked when double DPB1 mm was compared with zero mm in MA transplants, although the numbers Abbreviations: FBC ¼ fludarabine/busulphan/alemtuzumab conditioning; FMC ¼ fludarabine/melphalan/alemtuzumab condiyclophosphamide conditioning; Neg ¼ negative; Pos ¼ positive.
Effect of DPB1 mm on T-deplete PBSCT outcomes C Burt et al were small (60% vs 31% (P ¼ 0.11)). In our cohort, there was no demonstrable impact of nonpermissive or permissive T-cell epitope groups on OS in 10/10 transplants. There was no effect of combining permissive DP mm and fully DPB1-matched transplants and on comparing this group with those who were transplanted with grafts containing nonpermissive single or double DP mm. No effect on RR, NRM or event-free survival was seen in any of these subgroups, but the small sample size is a major caution to interpretation.
Associations between matching at 12 loci (HLA-A, B, C, DRB1, DQB1 and DPB1) and OS Mismatches were identified in 87% of patients previously considered fully matched (1DPmm ¼ 49pts: 2DPmm ¼ 28pts), Figure 1 . The effect of matching at 10 conventional loci (HLA-A, B, C, DRB1, DQB1) on the probability of OS (pOS) in T-cell-depleted PBSC transplants. The effect of matching at 9 vs 10 loci on pOS is shown in (a) the cohort overall, (b) in reduced-intensity and (c) myeloablative subsets, and (d) pOS is shown for patients with zero, one or two DPB1 mismatches in 10/10 transplants in the cohort overall. Two patients were 8/10 matched but 9/12 mismatched (single DQ, DR, DP mm) and hence were excluded from the 10/10 analysis; therefore, the total number of patients evaluable was 128.
Effect (Table 2) . Overall, there was a progressive improvement in OS when matching was considered for all 12 loci (Figure 2a) . However, as the numbers were small, we combined groups for statistical analysis. The 11/12 and 12/12 groups were compared using the log rank and Mann-Whitney U-tests and no differences in outcomes (OS, event-free survival, NRM, RR) were seen. Similarly, no differences were seen when 9/12 and 10/12 cohorts were compared. Subsequently, the combination of these groups allowed analysis of the effects of two or more HLA mm versus single or zero mm. This analysis showed that patients mismatched at 1 or 0 loci, effectively fully matched or single DP mismatches only (Table 2) , had significantly better OS than those with two or more mismatches (P ¼ 0.013) (Figure 2c ). This effect was mediated primarily by the beneficial effect of improved matching in the MA group (Figure 2d) , where 3-year OS rates were 59% if transplants were matched at 11 or 12 loci but only 28% if two or more cumulative mm were identified (P ¼ 0.02). By contrast, in patients conditioned with an RIC regimen, there was no difference in OS when two or more mm were compared with 1 or 0 mm (P ¼ 0.27). The detrimental effect on OS of mm at more than one loci remained significant in the multivariate analysis in the population as a whole. In a model including factors known to have an impact on transplant outcomes as covariates, that is, stratified CMV risk status and sex matching of host and donor, recipient and donor ages, disease type, disease stage and the intensity of conditioning, matching status at 12 loci was the strongest determinant of OS and the only independently significant variable in this analysis (Table 3 ). The hazard ratio of increased all-cause mortality in transplants mismatched at two or more loci was 1.8 (95% confidence interval 1.1-3.06 (P ¼ 0.017)).
Associations between matching at 12 loci and RRs In the cohort, the overall 3-year RR was 37% (Figure 3a ). There were no differences in RR between those patients who had received a transplant from donors mismatched at two or more loci and those who had received transplants from better matched donors (0 or 1 mm) when either MA (P ¼ 0.69) (Figure 3b ) or RIC regimens (P ¼ 0.43) were considered.
Associations between matching at 12 loci and the incidence of GVHD The incidence of grade III-IV classical acute GVHD (aGVHD) was low at 8% overall (5% MA; 11% RIC), and this was not a major cause of mortality. There was no significant effect on the incidence of severe aGVHD if mm at two or more loci were compared with zero or one mm, irrespective of the intensity of conditioning. The incidence of aGVHD I-IV was much higher, occurring in 60% of patients who received MA conditioning vs 54% of those receiving an RIC. In RIC patients, multiple mm did not increase the incidence of all grade aGVHD (P ¼ 0.18), but in the MA setting significantly more patients with two or more mm developed this complication, compared with those with 0 or 1 mismatches (77% vs 38%, P ¼ 0.027). The Figure 2 . Effect of matching at 12 loci (HLA-A, B, C, DRB1, DQB1, DPB1) on pOS. The effect of matching at 12 loci on pOS is shown. Panel a shows the pOS for different levels of matching at 12 loci in the cohort as a whole and panel b shows the same data for MA transplants. As described in the text, transplants in which 11 or 12 loci were matched, that is, 11/12 and 12/12, were combined and outcomes were compared with those with two or more mismatches, that is, 9/12 and 10/12. Panel c shows the effect of mismatching more than one loci on pOS in all patients in the cohort, and panel d shows the same effect in those patients receiving myeloablative conditioning.
Effect of DPB1 mm on T-deplete PBSCT outcomes C Burt et al incidence of late-onset acute and chronic GVHD was high in our cohort, possibly as a result of using PBSC as the stem cell source. Skin was the organ most commonly involved and this was often in advanced stage. The clinical behaviour in this group of PBSC recipients was commonly best described as late-onset aGVHD rather than as classical chronic GVHD. The incidence of late-onset acute and chronic GVHD at 3 years was 59% in the RIC cohort, with no difference seen if a graft with two or more mm was compared with closer matching (P ¼ 0.806). In MA patients, the combined incidence of late-onset acute and chronic GVHD was 40% in the group overall. Furthermore, there was a dramatic increase in the 3-year incidence of combined late-onset acute and chronic GVHD if more than a single locus was mismatched (16% vs 61%, P ¼ 0.018).
Associations between matching at 12 loci and nonrelapse mortality Overall, the NRM was 26% at 3 years. A significant reduction in NRM was observed in patients who received a graft matched at 11 or 12 loci compared with those with two or more cumulative mismatches (P ¼ 0.03). This effect was only apparent in those who had received an MA conditioning regimen where 3-year NRM was 9% vs 30% (P ¼ 0.039) (Figure 3b ), whereas in those conditioned with a reduced-intensity approach there was no difference in 3-year NRM rates (P ¼ 0.485).
DISCUSSION
Data are extensive when the effect of HLA-DPB1 mm on transplant outcomes is considered in the T-cell-replete setting, using BM as the stem cell source, 4,10-16 but much less has been published on T-cell-depleted PBSC transplantation. 4, 22 This single-centre study considered the effects of mm HLA-DPB1, alone and in combination with 10 standard HLA alleles, in a cohort of patients all receiving in vivo T-cell depletion and PBSC as a stem cell source. Our population is representative of the core population undergoing transplantation for acute leukaemia and MDS. No patients with early-stage leukaemia or CML were included, in contrast to most published registry-based studies. CML patients were deliberately excluded as the strong GVL effect and changing transplant practice in this disease entity were possible confounding factors.
We saw no effect on OS when single-locus mm for 10 conventional alleles was considered, nor did we see any statistically significant effect on OS when single DP mismatches alone were analysed in 10/10 matched transplants, although there was a distinct trend to worse OS with double DPB1 mm. This was most marked in the MA setting when double DPB1 mm was compared with fully matched recipients. We also saw no effect of T-cell epitope mismatching on transplant outcomes, but the Effect of DPB1 mm on T-deplete PBSCT outcomes C Burt et al numbers in these subsets were small. Striking differences in outcomes were seen, however, when DPB1 mm was considered in combination with matching at HLA-A, B, C, DRB1 and DQB1.
In the 12-allele analysis, we combined single mm, which was single DPB1 mm alone in 49/50 cases, and full matches and compared this new group of patients with those who had multiple mismatches. In these analyses, there was a statistically significant improvement in OS, NRM and GVHD rates with better matching. Thus, combining HLA-DPB1 matching status with matching for the 10 standard HLA alleles was highly discriminatory and could stratify outcomes when this was not apparent otherwise. Furthermore, we found this effect was dependent on the intensity of pretransplant conditioning.
In our patients conditioned with an RIC regimen, we saw no difference in OS even when two or more mm were present. This is in keeping with the published results examining the effects of mm in HLA-A, B, C, DRB1 and DQB1 in the RIC setting where alemtuzumab was shown to ameliorate the effect of multiple mm.
3 No significant differences were seen in acute or chronic GVHD, NRM or OS between 10/10 and 6-9/10 mm in lymphoid malignancies. 3 Our results in the MA setting are again similar to published data. Comparison with the largest existing study warrants consideration. 4 In this registry study, 83% of the patients had received T-cell depletion using alemtuzumab, although 76% had received BM as the stem cell source, and the patient population was significantly more heterogeneous than ours; in particular, 29% of patients had CML. 4 Despite these differences in patient populations, both studies have shown increased acute and chronic GVHD rates with cumulative mm, but a low absolute risk for severe aGVHD. Similarly, NRM was increased in both studies when multiple mm were studied.
However, there are two differences. Neither the previously described reduced RRs seen in any DPB1-mismatched transplant nor the beneficial effect of DPB1 mm on OS in late-stage disease were seen in our study. With respect to RR, the use of PBSC in our study may have reduced RR in matched recipients, or the alemtuzumab doses used here may have abrogated the beneficial effect in the DPB1-mismatched group. The absence of a demonstrable effect on RR seen in this relatively small study, although interesting, requires confirmation. With respect to OS benefit of mm in advanced-stage disease, it is possible that the high-risk patients described previously 4 were the major recipients of the T-cell-replete grafts, where the positive effects of mm may have been most marked. Importantly, the two populations are not directly comparable. We classified our patients using a recent modification of the Center for International Blood and Marrow Transplant Research criteria suggested by Woolfrey et al., 23 combining high-risk CR1 patients with those in CR2 as an intermediate-risk group. As such, our population draws elements from both the early-and late-stage groups defined in the previous study. 4 We cannot definitively comment on the effect of mm at 12 loci in advanced leukaemia (4CR2), as we had only two such patients, whereas OS in our MDS cohort was indistinguishable from that in our intermediate-risk patients.
The recognized limitation of this study is the small cohort size. This has prevented analysis of the impact of individual HLA loci mismatches including the potential role of disparity at HLA-DRB 3, 4, 5 loci. However, we found that the addition of HLA-DPB1 matching to conventional matching algorithms did have practical benefits. We agree with previous publications 410, 12 that matching between host and donor should be performed at 12 loci, including DPB1, in T-cell-depleted PBSC transplantation, when MA conditioning is employed. In acute leukaemia and MDS, as defined in our study population, we see no advantage of mm at DPB1. We now ideally select donors fully matched for HLA-A, B, C, DRB1, DQB1 and DPB1, although pragmatically we would accept a single mm while avoiding double mm when possible.
